PDF(Pubmed)
Abstract：
Gastric cancer is one of the most prevalent cancers worldwide, and human epidermal growth factor receptor 2 (HER2)-positive cases account for approximately 20% of the total cases. Currently, trastuzumab + chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer, and the combination has exhibited definite efficacy in HER2-targeted therapy. However, the emergence of drug resistance during treatment considerably reduces its effectiveness; thus, it is imperative to investigate the potential mechanisms underlying resistance. In the present review article, we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases, aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.
摘要：
胃癌是世界范围内最常见的癌症之一,和人类表皮生长因子受体2（HER2）阳性病例约占总病例的20％。目前,曲妥珠单抗+化疗是HER2阳性晚期胃癌患者推荐的一线治疗方法,并且该组合在HER2靶向治疗中表现出明确的疗效。然而,治疗过程中耐药性的出现大大降低了其有效性；因此，研究潜在的耐药机制势在必行.在本评论文章中，我们全面介绍了HER2阳性胃癌病例对曲妥珠单抗耐药的多种机制，旨在为纠正与曲妥珠单抗耐药相关的问题和制定后续治疗策略提供见解。
